Addyi Vaccine Interaction Profile: What Flibanserin Patients Need to Know

Does Flibanserin Interact With Vaccines?

Flibanserin does not interact with any approved vaccine. Vaccines work through immunological mechanisms, triggering antigen-specific adaptive immune responses without touching hepatic cytochrome P450 enzymes. Flibanserin is cleared almost entirely via CYP3A4-mediated oxidation, with a secondary contribution from CYP2C19. Because no licensed vaccine inhibits or induces CYP3A4 or CYP2C19, co-administration carries no pharmacokinetic consequence.

Why the Question Comes Up

Patients starting Addyi are enrolled in the FDA Risk Evaluation and Mitigation Strategy (REMS) program, which requires counseling on a defined list of prohibited substances. That counseling sometimes prompts patients to ask whether vaccines belong on the list. They do not. The FDA-approved Addyi prescribing information lists no vaccine as a contraindicated or cautioned co-administration. The full prescribing information is publicly available on the FDA label database and contains no vaccine-related interaction language. [1]

What the REMS Program Actually Covers

The Addyi REMS focuses on three interaction categories: alcohol, moderate-to-strong CYP3A4 inhibitors, and CNS depressants. Prescribers and pharmacies must be certified, and patients must sign a Patient-Provider Agreement before dispensing. The FDA REMS database entry for flibanserin confirms that vaccine administration is outside the scope of any REMS-mandated restriction. [2] Patients receiving flu shots, COVID-19 boosters, or any other routine immunization need not delay or adjust their flibanserin dose.

Immunization Schedule Recommendations

The CDC adult immunization schedule recommends annual influenza vaccination, age-appropriate Tdap, shingles (recombinant zoster vaccine), pneumococcal vaccines, and COVID-19 boosters based on current guidance. The 2024 CDC Adult Immunization Schedule lists no contraindication related to flibanserin or any non-immunosuppressive prescription drug. [3] Women taking Addyi for HSDD should follow the same schedule as the general adult population.

How Flibanserin Is Metabolized: The CYP3A4 Pathway

Understanding why vaccines pose no risk requires a brief look at how flibanserin is actually processed in the body. After a 100 mg oral dose, peak plasma concentration is reached in roughly 45 minutes, and the drug undergoes first-pass hepatic metabolism. CYP3A4 generates the primary metabolite (M1), while CYP2C19 produces a secondary metabolite (M2). Neither metabolite retains appreciable pharmacological activity at clinically observed concentrations.

CYP3A4: The Rate-Limiting Step

Any substance that slows CYP3A4 activity will raise flibanserin plasma levels. The prescribing label documents that co-administration with the moderate CYP3A4 inhibitor fluconazole 200 mg increased flibanserin AUC by 7-fold and Cmax by 2-fold, and caused symptomatic hypotension in four of six healthy female subjects studied. [1] That single data point explains why the REMS program prohibits concurrent fluconazole use.

Strong CYP3A4 inhibitors, including ketoconazole, itraconazole, clarithromycin, and ritonavir, carry the same or greater theoretical risk. The FDA-approved label lists these as contraindicated. [1] Grapefruit juice, a moderate CYP3A4 inhibitor, is also listed as a substance to avoid.

CYP2C19 and Genetic Variability

Roughly 2 to 3 percent of White adults and 4 to 5 percent of Black adults are CYP2C19 poor metabolizers. Research indexed at PubMed on CYP2C19 polymorphism prevalence confirms that poor metabolizers accumulate M2 at higher concentrations than extensive metabolizers. [4] The clinical consequence for flibanserin specifically has not been quantified in a dedicated pharmacogenomic trial, but prescribers should keep this variability in mind when patients report unexpected CNS side effects at standard doses.

Inducers Lower Efficacy

The opposite problem occurs with CYP3A4 inducers. Rifampin, carbamazepine, phenytoin, and St. John's Wort accelerate flibanserin clearance. A PubMed-indexed review of CYP3A4 induction mechanisms notes that potent inducers can reduce drug AUC by 50 to 90 percent for substrates with high extraction ratios. [5] For flibanserin, this translates to potential therapeutic failure. Patients who start a CYP3A4 inducer while on flibanserin may stop experiencing HSDD benefit without understanding why.

Alcohol: The Most Dangerous Flibanserin Interaction

Alcohol is the single most clinically consequential co-administration risk for flibanserin. The FDA required a dedicated alcohol interaction study before approving the drug. In that study, co-ingestion produced severe hypotension and syncope. The label carries a boxed warning, and the REMS program requires patients to agree to abstain from alcohol entirely while taking Addyi. [1]

What the Interaction Study Found

The alcohol-flibanserin interaction study enrolled 25 healthy volunteers in a cross-over design. Subjects received flibanserin 100 mg alone, alcohol 0.4 g/kg alone, alcohol 0.8 g/kg alone, and each alcohol dose combined with flibanserin. At the 0.8 g/kg dose (roughly two standard drinks), 4 of 23 evaluable subjects experienced syncope when taking flibanserin simultaneously, compared with 0 of 23 on alcohol alone. Systolic blood pressure fell by a mean of 19 mmHg greater in the combination arm. The FDA drug approval package for flibanserin contains the full study report. [6]

Mechanism of the Hypotensive Effect

Flibanserin is a 5-HT1A agonist and 5-HT2A antagonist with dopamine D4 receptor activity. Alcohol potentiates CNS depression independently of these targets. The combination impairs the baroreceptor reflex arc, allowing blood pressure to fall without the compensatory tachycardia that would normally occur. This is why the risk is not simply additive but appears supra-additive at moderate alcohol doses.

Practical Counseling Points

Patients frequently ask whether "one glass of wine" is safe. The answer from the prescribing label is no. The REMS agreement requires complete abstinence, not moderation. Patients who cannot commit to alcohol abstinence are not appropriate candidates for flibanserin. Prescribers should document this counseling and the signed Patient-Provider Agreement in the medical record.

CNS Depressant Interactions

Beyond alcohol, flibanserin interacts with any drug or supplement that depresses central nervous system function. The mechanism is additive CNS depression, not CYP-mediated pharmacokinetics.

Benzodiazepines and Sleep Agents

Benzodiazepines (diazepam, lorazepam, clonazepam), non-benzodiazepine hypnotics (zolpidem, eszopiclone), and barbiturates all deepen the sedative effect of flibanserin. Because flibanserin is taken at bedtime, patients may underestimate the additive risk of a concurrent sleep aid. Zolpidem CR 12.5 mg, for example, is associated with next-morning psychomotor impairment even when taken alone. A PubMed-indexed study on zolpidem and driving performance documents residual impairment at 8 hours post-dose in a proportion of subjects. [7] Adding flibanserin to that picture increases the risk of morning sedation, falls, and driving impairment.

Opioids and Muscle Relaxants

Opioid analgesics and centrally acting muscle relaxants (cyclobenzaprine, carisoprodol) compound sedation by similar additive mechanisms. The prescribing label instructs clinicians to use caution with all CNS depressants and to discuss the risk explicitly. For patients with chronic pain who require opioids, the risk-benefit calculation for flibanserin becomes more complex and should involve shared decision-making.

Diphenhydramine and OTC Antihistamines

First-generation antihistamines like diphenhydramine (found in many OTC sleep aids and allergy medications) have significant anticholinergic and sedative properties. Patients taking Addyi who also reach for a NyQuil or Benadryl at bedtime may experience pronounced morning grogginess. This is an underappreciated real-world interaction that is not always flagged in pharmacy systems.

Drug-Drug Interactions: A Systematic View

The table below organizes the major documented flibanserin interactions by mechanism and severity. This is not exhaustive. Always cross-check with the current FDA label and a clinical pharmacology database.

| Drug / Drug Class | Mechanism | Clinical Effect | Prescribing Label Action | |---|---|---|---| | Alcohol (ethanol) | CNS depression, baroreceptor impairment | Hypotension, syncope | Contraindicated (REMS) | | Fluconazole (moderate CYP3A4 inhibitor) | CYP3A4 inhibition | 7-fold AUC increase, hypotension | Contraindicated | | Ketoconazole, itraconazole (strong CYP3A4 inhibitors) | CYP3A4 inhibition | Expected greater AUC increase | Contraindicated | | Clarithromycin, ritonavir (strong CYP3A4 inhibitors) | CYP3A4 inhibition | Expected greater AUC increase | Contraindicated | | Grapefruit juice | Intestinal CYP3A4 inhibition | Moderate AUC increase | Avoid | | Rifampin, carbamazepine (strong CYP3A4 inducers) | CYP3A4 induction | Markedly reduced efficacy | Avoid | | St. John's Wort | CYP3A4 induction (moderate) | Reduced efficacy | Avoid | | Benzodiazepines, opioids, sleep agents | Additive CNS depression | Increased sedation, falls | Caution; discuss with patient | | Digoxin | P-glycoprotein competition | Flibanserin raises digoxin AUC by 29% | Monitor digoxin levels | | Any vaccine | None | No interaction | No restriction |

Sources: FDA prescribing label [1], FDA approval package [6].

Flibanserin and Digoxin: An Underappreciated Interaction

Digoxin deserves a separate mention because it is not a CYP substrate. Flibanserin inhibits P-glycoprotein (P-gp) transport, and digoxin is a narrow-therapeutic-index P-gp substrate. The prescribing label documents that flibanserin 100 mg once daily raised digoxin AUC by 29 percent and Cmax by 19 percent in a pharmacokinetic study. [1]

Clinical Significance

A 29 percent rise in digoxin AUC may push patients with borderline toxic levels into overt toxicity. Symptoms of digoxin toxicity include bradycardia, nausea, visual disturbances, and life-threatening arrhythmias. A PubMed-indexed pharmacology review on P-glycoprotein and cardiac drug interactions confirms that P-gp inhibition at the intestinal and renal level explains most clinically significant digoxin interactions. [8] Prescribers should check a baseline digoxin level before starting flibanserin in any patient taking digoxin and recheck 4 to 6 weeks after initiation.

The Clinical Efficacy Context: Why Patients Accept These Restrictions

Patients prescribed flibanserin have been diagnosed with HSDD, defined as low sexual desire causing marked distress. The BEGONIA trial (N=949) showed that flibanserin 100 mg nightly produced a statistically significant increase in satisfying sexual events (SSEs) versus placebo at 24 weeks, with a mean difference of approximately 0.5 SSEs per month (P<0.001). A PubMed record for the BEGONIA study is available at. [9] The Endocrine Society clinical practice guideline on female sexual dysfunction acknowledges HSDD as a medical condition warranting treatment and supports pharmacological options where appropriate. The Endocrine Society guideline on female sexual dysfunction states that "hypoactive sexual desire disorder is a well-characterized condition with validated diagnostic criteria and emerging pharmacotherapy options." [10]

Balancing Efficacy Against Interaction Risk

The modest but real efficacy data, roughly 0.5 additional SSEs per month above placebo, means that flibanserin provides genuine but limited benefit. Patients with significant alcohol use or polypharmacy involving multiple CYP3A4 inhibitors may find that the interaction burden outweighs the benefit. A shared decision-making conversation should address: (1) current alcohol use pattern, (2) full medication and supplement list, (3) realistic efficacy expectations, and (4) the commitment required by the REMS program.

Monitoring and Follow-Up After Starting Flibanserin

First 30 Days

The most common adverse effects in trials were dizziness (11.4%), somnolence (11.2%), nausea (10.4%), and fatigue (9.2%). [1] These typically peak in the first 2 to 4 weeks as the patient adjusts. Prescribers should schedule a 30-day follow-up call or visit to review tolerability and confirm ongoing alcohol abstinence.

Ongoing Monitoring

No specific laboratory monitoring is required for flibanserin itself, beyond digoxin levels in patients who also take that drug. Blood pressure can be measured at routine visits. If a patient needs to start a new medication during flibanserin therapy, the prescriber should check whether it is a CYP3A4 inhibitor, CYP3A4 inducer, or CNS depressant before proceeding. The PubMed-indexed FDA Drug Interactions guidance document provides a framework for evaluating metabolic drug interactions in clinical practice. [11]

When to Discontinue

Flibanserin should be discontinued if: a strong CYP3A4 inhibitor must be started, the patient resumes regular alcohol use, hepatic impairment is diagnosed, or the patient becomes pregnant. The prescribing label also notes that if no improvement is seen after 8 weeks at 100 mg nightly, discontinuation is appropriate because non-responders are unlikely to benefit from continued use.

Special Populations

Hepatic Impairment

Flibanserin is contraindicated in patients with any degree of hepatic impairment. Because CYP3A4 is expressed predominantly in hepatocytes, even moderate impairment substantially reduces drug clearance. The Child-Pugh scoring system categorizes hepatic impairment as mild (5 to 6 points), moderate (7 to 9 points), and severe (10 to 15 points). Flibanserin is contraindicated across all categories. [1]

Older Adults

The mean age of women enrolled in the key flibanserin trials was approximately 36 years. Data in women over 60 are sparse. Older adults are more susceptible to orthostatic hypotension, falls, and sedation from CNS-active agents. The American Geriatrics Society Beers Criteria flags CNS depressants as potentially inappropriate in older adults, and flibanserin's mechanism overlaps this concern. Prescribers should exercise extra caution in postmenopausal patients, noting that flibanserin is only FDA-approved for premenopausal HSDD.